Anakinra for Inflammatory Pustular Skin Diseases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01794117|
Recruitment Status : Completed
First Posted : February 18, 2013
Last Update Posted : June 12, 2020
|First Submitted Date ICMJE||February 15, 2013|
|First Posted Date ICMJE||February 18, 2013|
|Last Update Posted Date||June 12, 2020|
|Actual Study Start Date ICMJE||July 22, 2013|
|Actual Primary Completion Date||March 19, 2019 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Response rate [ Time Frame: 3 months ]
Patients who experience at least a 50% improvement in TBSAI
|Original Primary Outcome Measures ICMJE
||Obtain an estimate of the response rate to treatment [ Time Frame: 3 months ]|
|Current Secondary Outcome Measures ICMJE||Not Provided|
|Original Secondary Outcome Measures ICMJE
||Optimal dosing and safety [ Time Frame: 3 months ]|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title ICMJE||Anakinra for Inflammatory Pustular Skin Diseases|
|Official Title ICMJE||A Phase 2 Study of Anakinra in Inflammatory Pustular Dermatoses: Evaluation of Therapeutic Efficacy and Validation of Pathogenic Mechanisms|
- To see if anakinra can be used to treat inflammatory pustular skin disease.
- Individuals at least 18 years of age who have inflammatory pustular skin disease.
-To characterize the clinical efficacy, optimal dosing and safety of anakinra in patients with pustular dermatoses.
|Study Type ICMJE||Interventional|
|Study Phase ICMJE||Phase 2|
|Study Design ICMJE||Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Intervention ICMJE||Drug: Anakinra
An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If pustule formation persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4
|Study Arms ICMJE||Experimental: A
An initial dose of anakinra 100 mg/day will beadministered daily via self-administered subcutaneousinjection. If pustule formation persists at this dose,anakinra dose may be escalated up to 200 mg/dayinjected subcutaneously daily at week 4
Intervention: Drug: Anakinra
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Actual Enrollment ICMJE
|Original Estimated Enrollment ICMJE
|Actual Study Completion Date ICMJE||October 7, 2019|
|Actual Primary Completion Date||March 19, 2019 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
1.1 Females and males, aged greater than or equal to 18.
1.2 Patients must demonstrate active noninfectious inflammatory pustular skin lesions resembling pustular psoriasis and involving greater than or equal to 5% total body surface area, or palmoplantar involvement. Conditions may include, but are not be limited to, pustular psoriasis, Sneddon-Wilkinson disease, subcorneal pustular dermatosis, reactive arthritis, palmoplantar pustulosis, acrodermatitis continua of Hallopeau and palmoplantar pustular psoriasis.
1.3 Patients must have histopathologic confirmation of epidermal neutrophilic pustular skin disease.
1.4 If taking immunosuppressants, retinoids or anti-neutrophil therapy, participants must maintain stable doses of these medications during the 2 weeks prior to study initiation.
1.5 Patients must have stable topical medication regimen for 2 weeks prior to study initiation.
1.6 Patients must have normal organ and marrow function as defined below:
leukocytes greater than or equal to 3,000/mcL
absolute neutrophil count greater than or equal to1,500/mcL
platelets greater than or equal to 100,000/mcL
creatinine within normal institutional limits OR creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
1.7 Quantiferon TB Gold must be performed for screening for mycobacterium tuberculosis infection. However, a tuberculin skin test may be placed if the Quantiferon TB gold test is indeterminate. Patients must have a negative Quantiferon TB Gold (or tuberculin skin test) or evidence of appropriate treatment prior to study entry.
1.8 Patients must be able to understand and sign a written informed consent document and complete study-related procedures and questionnaires.
2.1 Enrollment in any other investigational treatment study or use of an investigational agent, or has not yet completed at least 3 half-lives since ending another investigational device or drug trial.
2.2 History of treatment with canakinumab within the 12 months prior to study initiation.
2.3 History of anakinra use.
2.4 History of phototherapy within 2 weeks prior to study initiation.
2.5 Patients may NOT concurrently be on biologic therapy such as etanercept, adalimumab, alefacept, infliximab, rituximab or rilonacept. If there is a history of use of biologic agents, there must be a washout period of at least 3 half-lives prior to study initiation.
2.6 Subjects who experience a significant flare after discontinuation of a TNF inhibitor as part of this study that requires urgent medical management or hospitalization, or in the estimation of the principal investigator poses excessive risk to the patient to enter the study.
2.7 Other defined dermatologic conditions which may include pustules as part of the clinical presentation, but which clinically and/or histologically do not resemble pustular psoriasis. Examples include, but are not limited to acute generalized exanthematous pustulosis (AGEP, a drug-induced pustular dermatosis typically caused by beta-lactam antibiotics, tetracyclines, oral antifungals and other drugs), bacterial or fungal folliculitis, cutaneous candidiasis, tinea pedis, tinea corporis, neutrophilic eccrine hidradenitis or eosinophilic pustular folliculitis (Ofuji syndrome).
2.8 Known diagnosis of DIRA.
2.9 History of allergic reactions attributed to compounds of similar chemical or biologic composition to anakinra or other agents used in study. Known hypersensitivity to CHO-cell derived biologics or any components of anakinra.
2.10 Treatment with a live virus vaccine during the 3 months prior to baseline visit. No live vaccines will be allowed throughout the course of this study.
2.11 Patients with active or untreated malignancy-- with the exception of cutaneous basal or squamous cell carcinomas, or in situ cervical carcinoma-- are ineligible because of the immunomodulating effects of anakinra. The risk of recurrent malignancy secondary to this drug is unknown.
2.12 Presence of active infection. History of exposure to TB (positive PPD or Quantiferon TB gold) who have not been treated with a TB prophylaxis regimen for at least one month.
2.13 Chest x-ray demonstrating pleural scarring and/or calcified granuloma consistent with prior or current untreated TB.
2.14 History of chronic or recurrent infection including but not limited to HIV, hepatitis B or hepatitis C.
2.15 Individuals with severe or uncontrolled recurrent cutaneous infections who are considered at elevated risk for serious infection on anakinra therapy will be excluded per physician discretion.
2.16 Presence of other known significant autoimmune or inflammatory disease. Examples include major chronic infectious/inflammatory/immunologic diseases such as systemic lupus erythematosus, rheumatoid arthritis, Sjogren s syndrome and periodic fever syndromes.
2.17 Other immunoregulatory or immunodeficiency diseases, such as multiple sclerosis.
2.18 Individuals with life-threatening or disabling inflammation of the eyes, gut or joints requiring urgent or immediate medical attention, or at the physician s discretion.
2.19 Subjects for whom there is concern about compliance with the protocol procedures.
2.20 Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled or unmonitored psychiatric illness/social situations, or history of congestive heart failure, unstable angina pectoris or medically significant cardiac arrhythmia that would limit compliance with study requirements.
2.21 Presence of other severe acute or chronic medical or psychiatric condition, or significant laboratory abnormality requiring further investigation that may cause undue risk for the subject's safety, inhibit protocol participation, or interfere with interpretation of study results, and in the judgment of the investigator would make the subject enrollment inappropriate.
2.22 The effects of anakinra on the developing human fetus are unknown. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Females of childbearing potential must have a negative serum pregnancy test at screening. Females must also have a negative serum pregnancy test at baseline and prior to performance of any radiologic procedure or administration of study medication and during each NIH visit. Lactating mothers will discontinue breastfeeding prior to study enrollment.
2.23 Pregnant or lactating females. Women of non-childbearing potential is defined as women who are postmenopausal (no menses for > one year) or who have had a hysterectomy and will not require B-HCG testing
|Ages ICMJE||18 Years to 110 Years (Adult, Older Adult)|
|Accepts Healthy Volunteers ICMJE||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT01794117|
|Other Study ID Numbers ICMJE||130071
|Has Data Monitoring Committee||Not Provided|
|U.S. FDA-regulated Product||
|IPD Sharing Statement ICMJE||Not Provided|
|Responsible Party||National Institutes of Health Clinical Center (CC) ( National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) )|
|Study Sponsor ICMJE||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|
|Collaborators ICMJE||Not Provided|
|PRS Account||National Institutes of Health Clinical Center (CC)|
|Verification Date||May 13, 2020|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP